Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin…
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 11, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage…
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 11, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage…
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE)…
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE)…
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global
Blue-Zone to install its patented anesthetic capture technology in Respirair manufacturing facility TORONTO, April 11,…
Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global
Blue-Zone to install its patented anesthetic capture technology in Respirair manufacturing facility TORONTO, April 11,…
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with…
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with…
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…